Best Monona County Grants for Nonprofits in Iowa

American Psychiatric Association Foundation

There is no health without mental health. The APA Foundation is working in your community to provide the support and resources we all need to prioritize mental wellbeing where you live, learn, work, worship, and play.

Backed by the medical expertise of the APA and industry-leading strategic partners, we administer community-changing programs, public education campaigns, grants, and awards aimed at increasing mental health literacy, connecting individuals to needed care, and shifting attitudes toward mental health.

Our Mission is to promote the mental health and well-being of individuals and communities. Our Vision is a mentally healthy nation for all – where we live, learn, work, worship, and play.

Diversity Leadership Fellowship

The Diversity Leadership Fellowship identifies and motivates minority psychiatry residents or those interested in minority and vulnerable populations to become well equipped to teach, administer, and provide culturally competent, evidence based mental health and substance abuse services to diverse minority groups and at-risk populations. These populations include—but are not limited to—American Indians/Native Alaskans, Asian Americans/Native Hawaiians/Native Pacific Islanders, Blacks/African Americans, Hispanics/Latinos, LGBTQ, and religious minorities. Program Benefits:

• Sponsorship to attend a minimum of four APA meetings:
  • Two APA Annual Meetings
  • Two Fellowship Forums
• Develop leadership skills in the field of psychiatry and advance understanding of the life experiences of racial ethnic minority communities
• Gain an understanding of APA/APAF Governance through observation and service on an APA Council, Committee, or APAF initiative
• Have the opportunity to sit on the APAF Board of Directors as a non-voting member (one Diversity Leadership fellow allowed)
• Cultivate a professional network with psychiatrists interested in minority mental health and services through exclusive events and engagements with APA leaders. Establish relationships and peer-mentorship with a diverse group of resident fellows with similar career interests and goals

Alkermes

At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders, including addiction, serious mental illness and sleep disorders. With our portfolio of marketed medicines and investigational pipeline candidates, we seek to make a meaningful difference in the way people manage these chronic diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.

Our greatest strengths at Alkermes are our people and our inherent empathy for patients, families and caregivers. Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We work with urgency to develop new treatment options for people living with these conditions.

Investigator Sponsored Studies Program

Alkermes seeks to support research designed and conducted by independent clinicians and scientists through our Investigator Sponsored Studies (ISS) program. Alkermes may occasionally announce a Request for Proposals (RFP) for research in clinical areas where gaps in data have been identified. 

The ISS research Alkermes supports must be based in the United States and is typically conducted by experienced researchers who have an established history of successfully completing research with independent funding. Alkermes can provide its marketed products to the ISS programs it supports. In addition, there may be financial support available, but please note that study budgets cannot exceed $300,000 (inclusive of overhead).

• ISS Areas of Interest
  • Sleep Disorders
  • Schizophrenia & Bipolar I Disorder
  • Schizophrenia

Alkermes

At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders, including addiction, serious mental illness and sleep disorders. With our portfolio of marketed medicines and investigational pipeline candidates, we seek to make a meaningful difference in the way people manage these chronic diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.

Our greatest strengths at Alkermes are our people and our inherent empathy for patients, families and caregivers. Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We work with urgency to develop new treatment options for people living with these conditions.

Pathways APN Research Awards

The Alkermes Pathways Advanced Practice Nurse (APN) Research Awards™ program is designed to empower the advanced practice nursing community by offering funding opportunities that recognize their vital role in evidence-based care and the advancement of mental health research.

The Alkermes Pathways APN Research Awards provide opportunities for individual grants of up to $10,000 per project for licensed psychiatric-mental health nurse practitioners who are actively engaged in clinical, academic, and/or community health settings and are committed to advancing research in schizophrenia or bipolar I disorder.

Interface Health Foundation

Interface Health Foundation is a non-profit, 501c3 tax-exempt organization driven by a collective vision of positive change. In healthcare industry policy, understanding the intricate dynamics of funding and its impact on public access, quality, and cost remains paramount. IHF is dedicated to advancing analysis and research into the crossroads of healthcare industry policy, structural frameworks and affordability.

At IHF, our mission is clear: to empower and support student-led research endeavors that shed light on critical healthcare policy and structural issues affecting the public. Through our initiatives, we seek to foster a deeper understanding of the complex dynamics shaping the healthcare landscape.

Interface Health Foundation: Research Grant

Healthcare administrative grant award opportunities are highly competitive and allow candidates to stand out as they enter the job market. Through this IHF grant award, you will get the opportunity to pull together research and content on topics that aren't fully studied or publicized. Depending on the grant topic, some grantees will also have access to a preceptor who is an executive leader in the healthcare field. The preceptor will serve as a valuable resource to the grantee during the development of the research paper and beyond.

An example of a research topic is the impact of legislated acute care nurse staffing levels on the following: nursing professional job satisfaction, the patient experience, and the standard nursing quality indicators as part of nursing Magnet status accreditation.

Mary Kay Ash Foundation

Guided by Mary Kay Ash’s dream to enrich the lives of women everywhere, the Mary Kay Ash Foundation® raises and distributes funds to invest in breakthrough cancer research and clinical trials to find a cure for women-related cancers and ending domestic violence.

Since 1996, the Mary Kay Ash Foundation®, a 501(c)3 organization, has contributed more than $100 million to organizations aligned with its two-fold mission. In addition, the Foundation supports awareness initiatives, community outreach programs, and advocates for legislation to ensure women are healthy and safe. Through our global charitable foundations in Brazil, Canada, China and the United States, we are collectively making a deeper impact on the lives of women around the world.

Mary Kay Ash Foundation: Cancer Research Grant

The Mary Kay Ash Foundation is a non-profit public foundation, which focuses on funding research for innovative grants for translational research of cancers affecting women (ovarian, uterine, breast, endometrial or cervical cancer among others). Translational research is broadly defined as research that will provide a scientific link between laboratory research and the clinic. Ultimately, such research would lead to improvement in diagnosis, prognosis, prevention, or treatment of the cancer. Each year the Foundation extends invitations to NCI designated cancer institutes and accredited medical schools to apply. Only one application is accepted per institution.

Grant proposals are reviewed by a Scientific Research Review Committee comprised of notable members of the American medical and scientific community. Grants are awarded up to $100,000 (combined direct and indirect costs) for a two-year period. The Foundation anticipates funding between 10 and 15 grants annually. 

Multiplex Platforms to Assess Indicators of Micronutrient Status, Inflammation and Infectious Disease

The Challenge

Although combined immunological measurement of several micronutrient biomarkers has been demonstrated, current methods still have important limitations. These include heterogeneity in the composition of standards and controls; inconsistent batch-to-batch performance of analyte-binding molecules; variable reactivity for some analytes, especially soluble transferrin receptor (sTfR); and a functional analytical range that is too narrow to cover the physiological values of some analytes, such as CRP. It would also be valuable to add bioindicators for vitamins B1, B2, B9 and B12, which may require binding molecules that recognize metabolites or proteins associated with deficiency, a specific vitamer (plasma methyl-tetrahydrofolate without reacting with folic acid), comparable reactivity across vitamers (several folate forms in red blood cells), or a specific carrier-protein form (holo-transcobalamin rather than apo-transcobalamin or haptocorrin for vitamin B12).

The improved assays must combine high analytical specificity, sensitivity and robustness with a functional analytical range matched to the physiological values expected in the target populations (women of reproductive age, including during pregnancy and lactation, preschool-age children and older adults). Assays must remain low-cost (no more than US$20 for all analytes measured in duplicate) and require very small sample volumes, preferably less than 10 µL of plasma or serum). The tests are intended for population surveillance rather than local clinical (point-of-care) use. They should be designed to run many samples in a single batch in a small number of national or regional reference laboratories. The goal is to reduce dependence on expensive, infrequent population surveys and on export of samples to specialized laboratories in high-income settings.

This challenge is structured around two alternatives, a minimum-scope approach and an optimistic-scope approach. Targets are aligned with the candidate Target Product Profile for this platform, and applicants will be held to the relevant performance, cost and instrument targets.

Multiplex Platforms to Assess Indicators of Micronutrient Status, Inflammation and Infectious Disease

The Challenge

Although combined immunological measurement of several micronutrient biomarkers has been demonstrated, current methods still have important limitations. These include heterogeneity in the composition of standards and controls; inconsistent batch-to-batch performance of analyte-binding molecules; variable reactivity for some analytes, especially soluble transferrin receptor (sTfR); and a functional analytical range that is too narrow to cover the physiological values of some analytes, such as CRP. It would also be valuable to add bioindicators for vitamins B1, B2, B9 and B12, which may require binding molecules that recognize metabolites or proteins associated with deficiency, a specific vitamer (plasma methyl-tetrahydrofolate without reacting with folic acid), comparable reactivity across vitamers (several folate forms in red blood cells), or a specific carrier-protein form (holo-transcobalamin rather than apo-transcobalamin or haptocorrin for vitamin B12).

The improved assays must combine high analytical specificity, sensitivity and robustness with a functional analytical range matched to the physiological values expected in the target populations (women of reproductive age, including during pregnancy and lactation, preschool-age children and older adults). Assays must remain low-cost (no more than US$20 for all analytes measured in duplicate) and require very small sample volumes, preferably less than 10 µL of plasma or serum). The tests are intended for population surveillance rather than local clinical (point-of-care) use. They should be designed to run many samples in a single batch in a small number of national or regional reference laboratories. The goal is to reduce dependence on expensive, infrequent population surveys and on export of samples to specialized laboratories in high-income settings.

This challenge is structured around two alternatives, a minimum-scope approach and an optimistic-scope approach. Targets are aligned with the candidate Target Product Profile for this platform, and applicants will be held to the relevant performance, cost and instrument targets.

Innovations in Low-Cost and Simplified Pathogen Sequencing Workflows

Catalyzing Innovation through Partnerships

At its core, Grand Challenges catalyzes bold innovation through partnership - bringing together funders, researchers, implementers, and public health leaders to solve complex global challenges. This multi-partner initiative reflects the Grand Challenges ethos, leveraging complementary expertise and investments to accelerate accessible genomic sequencing solutions for low- and middle-income Countries.

About this Challenge

This Grand Challenge is co-funded by the Gates Foundation, and the Temasek Foundation, and will be managed by the United Nations Foundation. This Grand Challenge is implemented in collaboration with a network of global and regional partners, including International Pathogen Surveillance Network (IPSN), hosted by the WHO Hub for Pandemic and Epidemic Intelligence, the Africa Pathogen Genomics Initiative (Africa PGI), and the Asia Pathogen Genomics Initiative (Asia PGI) as regional technical and public-health partners. This RFP aims to accelerate the development of affordable, scalable, and operationally simple sequencing solutions, enabling routine use of genomics for public health in low- and middle-income countries (LMICs).

Award Structure and Funding Level

To accommodate different stages of innovation maturity, this RFP supports a tiered award structure, with funding levels and expectations aligned to the readiness and scope of the proposed work. Indicative award categories are:

For technically ambitious or higher-risk, earlier-stage concepts focused on feasibility testing, assay or workflow prototyping, and initial cost-reduction validation. Intended approaches that require focused development to demonstrate viability.

Innovations in Low-Cost and Simplified Pathogen Sequencing Workflows

Catalyzing Innovation through Partnerships

At its core, Grand Challenges catalyzes bold innovation through partnership - bringing together funders, researchers, implementers, and public health leaders to solve complex global challenges. This multi-partner initiative reflects the Grand Challenges ethos, leveraging complementary expertise and investments to accelerate accessible genomic sequencing solutions for low- and middle-income Countries.

About this Challenge

This Grand Challenge is co-funded by the Gates Foundation, and the Temasek Foundation, and will be managed by the United Nations Foundation. This Grand Challenge is implemented in collaboration with a network of global and regional partners, including International Pathogen Surveillance Network (IPSN), hosted by the WHO Hub for Pandemic and Epidemic Intelligence, the Africa Pathogen Genomics Initiative (Africa PGI), and the Asia Pathogen Genomics Initiative (Asia PGI) as regional technical and public-health partners. This RFP aims to accelerate the development of affordable, scalable, and operationally simple sequencing solutions, enabling routine use of genomics for public health in low- and middle-income countries (LMICs).

Award Structure and Funding Level

To accommodate different stages of innovation maturity, this RFP supports a tiered award structure, with funding levels and expectations aligned to the readiness and scope of the proposed work. Indicative award categories are:

For concepts with preliminary feasibility evidence that are ready to advance from prototype toward an integrated workflow—optimizing performance, broadening assay or pathogen coverage, and generating more robust cost-reduction and performance data.

Innovations in Low-Cost and Simplified Pathogen Sequencing Workflows

Catalyzing Innovation through Partnerships

At its core, Grand Challenges catalyzes bold innovation through partnership - bringing together funders, researchers, implementers, and public health leaders to solve complex global challenges. This multi-partner initiative reflects the Grand Challenges ethos, leveraging complementary expertise and investments to accelerate accessible genomic sequencing solutions for low- and middle-income Countries.

About this Challenge

This Grand Challenge is co-funded by the Gates Foundation, and the Temasek Foundation, and will be managed by the United Nations Foundation. This Grand Challenge is implemented in collaboration with a network of global and regional partners, including International Pathogen Surveillance Network (IPSN), hosted by the WHO Hub for Pandemic and Epidemic Intelligence, the Africa Pathogen Genomics Initiative (Africa PGI), and the Asia Pathogen Genomics Initiative (Asia PGI) as regional technical and public-health partners. This RFP aims to accelerate the development of affordable, scalable, and operationally simple sequencing solutions, enabling routine use of genomics for public health in low- and middle-income countries (LMICs).

Award Structure and Funding Level

To accommodate different stages of innovation maturity, this RFP supports a tiered award structure, with funding levels and expectations aligned to the readiness and scope of the proposed work. Indicative award categories are:

For more mature concepts aimed at workflow refinement, performance optimization, and generation of proof-of-concept and validation data in relevant public-health use cases in LMICs.

About The American Chestnut Foundation:

Our mission is to return the iconic American chestnut to its native range.

Our vision is a robust eastern forest returned to its splendor.

Small Grants Program

Are you looking for funding to support your American chestnut research? External small grants offer recipients a variety of benefits such as professional development and an expanded network. Grant activities contribute to the continuous renewal and development of faculty and staff, to the education and motivation of students, and achievement of our mutual interest — restoration of the American chestnut. This is a small grants program. TACF does not ordinarily fund projects in excess of $10,000.